Kennedy Capital Management’s Rapport Therapeutics RAPP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$8.46M Buy
251,912
+1,117
+0.4% +$48.2K 0.16% 214
2026
Q2
$10.5M Sell
250,795
-6,636
-3% -$244K 0.19% 187
2026
Q1
$8.06M Buy
257,431
+78,694
+44% +$2.21M 0.17% 204
2025
Q4
$5.42M Buy
+178,737
New +$4.95M 0.11% 282
2025
Q3
– Sell
-11,230
Closed -$128K – 622
2025
Q2
$128K Buy
+11,230
New +$119K ﹤0.01% 577

Other funds holding RAPP

Kennedy Capital Management's RAPP Position: Q3 2026 in Review

Kennedy Capital Management increased its Rapport Therapeutics (RAPP) stake by 0.45% in Q3 2026, buying an estimated $48.2K and bringing the position to 251,912 shares worth $8.46M. The position accounts for 0.16% of the portfolio, ranked #214.

Kennedy Capital Management first reported a position in RAPP in Q2 2025 and has held it in 5 quarters since. The position peaked at $10.5M in Q2 2026. 169 funds tracked by Wall St. Rank hold RAPP as of Q3 2026.

  • Kennedy Capital Management held 251,912 shares of Rapport Therapeutics worth $8.46M as of Q3 2026.
  • Kennedy Capital Management bought 1,117 Rapport Therapeutics shares in Q3 2026, an estimated $48.2K.
  • Rapport Therapeutics made up 0.16% of Kennedy Capital Management's portfolio in Q3 2026, its #214 holding.
  • Kennedy Capital Management first reported a position in Rapport Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Kennedy Capital Management's Rapport Therapeutics position peaked at $10.5M in Q2 2026.
  • 169 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q3 2026.

Based on Kennedy Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.